NASDAQ · MLAB
Technology · Hardware, Equipment & Parts
$120.91
Up+$1.52 (+1.26%)
Updated Sep 11, 2026, 2:49 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MLAB closed at $120.91 after 20 trading sessions, up 6.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $122.43 | $124.70 | $120.69 | $120.91 | 171.66K |
| Sep 9, 2026 | $124.00 | $126.075 | $123.24 | $123.91 | 127.8K |
| Sep 8, 2026 | $127.18 | $127.18 | $123.135 | $123.74 | 148.56K |
| Sep 4, 2026 | $126.09 | $128.29 | $125.35 | $127.78 | 100.6K |
| Sep 3, 2026 | $131.47 | $132.70 | $127.80 | $128.53 | 127.45K |
| Sep 2, 2026 | $125.18 | $131.43 | $125.18 | $130.65 | 139.02K |
| Sep 1, 2026 | $127.13 | $128.275 | $124.24 | $125.47 | 116.03K |
| Aug 31, 2026 | $127.97 | $129.44 | $123.59 | $127.87 | 155.88K |
| Aug 28, 2026 | $127.81 | $129.66 | $126.79 | $129.09 | 153.08K |
| Aug 27, 2026 | $127.33 | $129.16 | $125.75 | $128.65 | 158.26K |
| Aug 26, 2026 | $127.10 | $127.9199 | $125.22 | $127.15 | 110.87K |
| Aug 25, 2026 | $124.32 | $128.69 | $122.00 | $127.35 | 142.12K |
| Aug 24, 2026 | $124.76 | $125.30 | $120.6725 | $124.32 | 148.32K |
| Aug 21, 2026 | $119.94 | $124.89 | $119.03 | $124.76 | 160.69K |
| Aug 20, 2026 | $118.47 | $121.90 | $118.47 | $119.15 | 185.39K |
| Aug 19, 2026 | $109.91 | $120.45 | $108.85 | $119.72 | 236.47K |
| Aug 18, 2026 | $106.66 | $109.35 | $105.065 | $107.94 | 194.22K |
| Aug 17, 2026 | $105.05 | $110.96 | $103.94 | $107.64 | 139.57K |
| Aug 14, 2026 | $113.09 | $115.43 | $105.24 | $106.04 | 161.03K |
| Aug 13, 2026 | $112.21 | $115.52 | $110.215 | $113.20 | 254.29K |
The latest Smart Investors Daily articles mentioning MLAB.
MLAB research
Company profile and research snapshot.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Wells Fargo | Equal-Weight | — |
| Feb 4, 2026 | Wells Fargo | Equal-Weight | — |
| Dec 15, 2025 | Wells Fargo | Equal-Weight | — |
| Aug 8, 2025 | Wells Fargo | Equal-Weight | — |
| May 30, 2025 | Wells Fargo | Underweight | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Wells Fargo analyst Evan Stampler maintains Mesa Laboratories (NASDAQ:MLAB) with a Equal-Weight and raises the price target from $94 to $110.
SeekingAlpha · Aug 10, 2026
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsDoug FarrellSiddhartha Kadia - CEO, President &...
Benzinga · Aug 10, 2026
Mesa Laboratories (NASDAQ:MLAB) reported quarterly earnings of $2.68 per share which beat the analyst consensus estimate of $2.40 by 11.67 percent. This is a 15.52 percent increase over earnings of $2.32 per share from
ChartMill · May 27, 2026
Mesa Labs Q4 results show EPS surging past estimates at $2.76, but revenue of $63.7M missed forecasts. Stock dips 2% pre-market as investors focus on the top-line shortfall.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MLAB.
